Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?

Lavoz C, Rayego-Mateos S, Orejudo M, Opazo-Ríos L, Marchant V, Marquez-Exposito L, Tejera-Muñoz A, Navarro-González JF, Droguett A, Ortiz A, Egido J, Mezzano S, Rodrigues-Diez RR, Ruiz-Ortega M.

J Clin Med. 2020 Jan 19;9(1). pii: E272. doi: 10.3390/jcm9010272. Review.

PMID:
31963845
2.

New information on phosphate binder interactions with vitamin K.

Bover J, Navarro-González JF, daSilva I.

Nefrologia. 2019 Dec 24. pii: S0211-6995(19)30191-2. doi: 10.1016/j.nefro.2019.10.001. [Epub ahead of print] English, Spanish. No abstract available.

3.

A terrestrial gamma-ray flash and ionospheric ultraviolet emissions powered by lightning.

Neubert T, Østgaard N, Reglero V, Chanrion O, Heumesser M, Dimitriadou K, Christiansen F, Budtz-Jørgensen C, Kuvvetli I, Rasmussen IL, Mezentsev A, Marisaldi M, Ullaland K, Genov G, Yang S, Kochkin P, Navarro-Gonzalez J, Connell PH, Eyles CJ.

Science. 2020 Jan 10;367(6474):183-186. doi: 10.1126/science.aax3872. Epub 2019 Dec 11.

PMID:
31826957
4.

Fibroblast growth factor 23 expression in human calcified vascular tissues.

Donate-Correa J, Martín-Núñez E, Hernández-Carballo C, Ferri C, Tagua VG, Delgado-Molinos A, López-Castillo Á, Rodríguez-Ramos S, Cerro-López P, López-Tarruella VC, Felipe-García R, Arévalo-Gomez MA, Pérez-Delgado N, Mora-Fernández C, Navarro-González JF.

Aging (Albany NY). 2019 Sep 22;11(18):7899-7913. doi: 10.18632/aging.102297. Epub 2019 Sep 22.

5.

Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?

Fernandez-Fernandez B, Fernandez-Prado R, Górriz JL, Martinez-Castelao A, Navarro-González JF, Porrini E, Soler MJ, Ortiz A.

Clin Kidney J. 2019 May 31;12(3):313-321. doi: 10.1093/ckj/sfz070. eCollection 2019 Jun.

6.

A Novel Heterozygous Deletion Variant in KLOTHO Gene Leading to Haploinsufficiency and Impairment of Fibroblast Growth Factor 23 Signaling Pathway.

Martín-Núñez E, Donate-Correa J, Kannengiesser C, De Brauwere DP, Leroy C, Oudin C, Friedlander G, Prieto-Morín C, Tagua VG, Ureña-Torres PA, Navarro-González JF.

J Clin Med. 2019 Apr 12;8(4). pii: E500. doi: 10.3390/jcm8040500.

7.

FGF23 and Klotho Levels are Independently Associated with Diabetic Foot Syndrome in Type 2 Diabetes Mellitus.

Donate-Correa J, Martín-Núñez E, Ferri C, Hernández-Carballo C, Tagua VG, Delgado-Molinos A, López-Castillo Á, Rodríguez-Ramos S, Cerro-López P, López-Tarruella VC, Arévalo-González MA, Pérez-Delgado N, Mora-Fernández C, Navarro-González JF.

J Clin Med. 2019 Apr 3;8(4). pii: E448. doi: 10.3390/jcm8040448.

8.

Pentoxifylline for Renal Protection in Diabetic Kidney Disease. A Model of Old Drugs for New Horizons.

Donate-Correa J, Tagua VG, Ferri C, Martín-Núñez E, Hernández-Carballo C, Ureña-Torres P, Ruiz-Ortega M, Ortiz A, Mora-Fernández C, Navarro-González JF.

J Clin Med. 2019 Feb 27;8(3). pii: E287. doi: 10.3390/jcm8030287. Review.

9.

Pharmacological interactions of phosphate binders.

Bover Sanjuán J, Navarro-González JF, Arenas MD, Torregrosa JV, Tamargo Menéndez J, de Francisco ALM, González-Parra E, Lloret Cora MJ, Sánchez Álvarez JE, Martín-Malo A, Molina Vila P, Bajo MA, DaSilva Santos I.

Nefrologia. 2018 Nov - Dec;38(6):573-578. doi: 10.1016/j.nefro.2018.05.003. Epub 2018 Jul 7. English, Spanish. No abstract available.

10.

Will the new molecules be effective in renal and cardiovascular protection in diabetes mellitus and diabetic kidney disease?

Martinez Martinez-Castelao A, Soler MJ, Navarro-González JF, Górriz JL.

Nefrologia. 2019 Jan - Feb;39(1):3-10. doi: 10.1016/j.nefro.2018.05.011. Epub 2018 Oct 2. English, Spanish. No abstract available.

11.

Inflammation in Diabetic Kidney Disease.

Pérez-Morales RE, Del Pino MD, Valdivielso JM, Ortiz A, Mora-Fernández C, Navarro-González JF.

Nephron. 2019;143(1):12-16. doi: 10.1159/000493278. Epub 2018 Oct 1. Review.

12.

Association of the rs495392 Klotho polymorphism with atheromatosis progression in patients with chronic kidney disease.

Valdivielso JM, Bozic M, Galimudi RK, Bermudez-López M, Navarro-González JF, Fernández E, Betriu À.

Nephrol Dial Transplant. 2019 Dec 1;34(12):2079-2088. doi: 10.1093/ndt/gfy207.

PMID:
30010839
13.

Effects of Pentoxifylline on Soluble Klotho Concentrations and Renal Tubular Cell Expression in Diabetic Kidney Disease.

Navarro-González JF, Sánchez-Niño MD, Donate-Correa J, Martín-Núñez E, Ferri C, Pérez-Delgado N, Górriz JL, Martínez-Castelao A, Ortiz A, Mora-Fernández C.

Diabetes Care. 2018 Aug;41(8):1817-1820. doi: 10.2337/dc18-0078. Epub 2018 Jun 4.

PMID:
29866645
14.

Phenotypic Modulation of Cultured Primary Human Aortic Vascular Smooth Muscle Cells by Uremic Serum.

Cazaña-Pérez V, Cidad P, Donate-Correa J, Martín-Núñez E, López-López JR, Pérez-García MT, Giraldez T, Navarro-González JF, Alvarez de la Rosa D.

Front Physiol. 2018 Feb 12;9:89. doi: 10.3389/fphys.2018.00089. eCollection 2018.

15.

The UCSC Genome Browser database: 2018 update.

Casper J, Zweig AS, Villarreal C, Tyner C, Speir ML, Rosenbloom KR, Raney BJ, Lee CM, Lee BT, Karolchik D, Hinrichs AS, Haeussler M, Guruvadoo L, Navarro Gonzalez J, Gibson D, Fiddes IT, Eisenhart C, Diekhans M, Clawson H, Barber GP, Armstrong J, Haussler D, Kuhn RM, Kent WJ.

Nucleic Acids Res. 2018 Jan 4;46(D1):D762-D769. doi: 10.1093/nar/gkx1020.

16.

Soluble levels and endogenous vascular gene expression of KLOTHO are related to inflammation in human atherosclerotic disease.

Martín-Núñez E, Donate-Correa J, López-Castillo Á, Delgado-Molinos A, Ferri C, Rodríguez-Ramos S, Cerro P, Pérez-Delgado N, Castro V, Hernández-Carballo C, Mora-Fernández C, Navarro-González JF.

Clin Sci (Lond). 2017 Oct 25;131(21):2601-2609. doi: 10.1042/CS20171242. Print 2017 Nov 1.

PMID:
28963437
17.

ERBP guideline on management of patients with diabetes and chronic kidney disease stage 3B or higher. Metformin for all?

Martínez-Castelao A, Górriz JL, Ortiz A, Navarro-González JF.

Nefrologia. 2017 Nov - Dec;37(6):567-571. doi: 10.1016/j.nefro.2017.06.001. Epub 2017 Jun 29. English, Spanish. No abstract available.

18.

Anti-inflammatory profile of paricalcitol in kidney transplant recipients.

Donate-Correa J, Henríquez-Palop F, Martín-Núñez E, Hernández-Carballo C, Ferri C, Pérez-Delgado N, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF.

Nefrologia. 2017 Nov - Dec;37(6):622-629. doi: 10.1016/j.nefro.2017.03.028. Epub 2017 Jun 15. English, Spanish.

19.

Urinary Clara Cell Protein in Kidney Transplant Patients: A Preliminary Study.

García-García PM, Martín-Izquierdo E, de Basoa CM, Jarque-López A, Pérez-Suárez G, Rivero-González A, González-Posadas JM, Macía-Heras M, García-Nieto VM, Navarro-Gónzález JF.

Transplant Proc. 2016 Nov;48(9):2884-2887. doi: 10.1016/j.transproceed.2016.09.022.

PMID:
27932098
20.

Effect of Paricalcitol on FGF-23 and Klotho in Kidney Transplant Recipients.

Donate-Correa J, Henríquez-Palop F, Martín-Núñez E, Pérez-Delgado N, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF.

Transplantation. 2016 Nov;100(11):2432-2438.

PMID:
27467536
21.

What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?

Molina P, Górriz JL, Molina MD, Beltrán S, Vizcaíno B, Escudero V, Kanter J, Ávila AI, Bover J, Fernández E, Nieto J, Cigarrán S, Gruss E, Fernández-Juárez G, Martínez-Castelao A, Navarro-González JF, Romero R, Pallardó LM.

World J Nephrol. 2016 Sep 6;5(5):471-81. doi: 10.5527/wjn.v5.i5.471.

22.

Implications of Fibroblast growth factor/Klotho system in glucose metabolism and diabetes.

Donate-Correa J, Martín-Núñez E, Delgado NP, de Fuentes MM, Arduan AO, Mora-Fernández C, Navarro González JF.

Cytokine Growth Factor Rev. 2016 Apr;28:71-7. doi: 10.1016/j.cytogfr.2015.12.003. Epub 2015 Dec 10. Review.

PMID:
26706229
23.

Klotho in cardiovascular disease: Current and future perspectives.

Donate-Correa J, Martín-Núñez E, Mora-Fernández C, Muros-de-Fuentes M, Pérez-Delgado N, Navarro-González JF.

World J Biol Chem. 2015 Nov 26;6(4):351-7. doi: 10.4331/wjbc.v6.i4.351. Review.

24.

Influence of Klotho gene polymorphisms on vascular gene expression and its relationship to cardiovascular disease.

Donate-Correa J, Martín-Núñez E, Martínez-Sanz R, Muros-de-Fuentes M, Mora-Fernández C, Pérez-Delgado N, Navarro-González JF.

J Cell Mol Med. 2016 Jan;20(1):128-33. doi: 10.1111/jcmm.12710. Epub 2015 Nov 5.

25.

Nephroprotection by Hypoglycemic Agents: Do We Have Supporting Data?

Górriz JL, Nieto J, Navarro-González JF, Molina P, Martínez-Castelao A, Pallardó LM.

J Clin Med. 2015 Oct 23;4(10):1866-89. doi: 10.3390/jcm4101866. Review.

26.

Horizon 2020 in Diabetic Kidney Disease: The Clinical Trial Pipeline for Add-On Therapies on Top of Renin Angiotensin System Blockade.

Perez-Gomez MV, Sanchez-Niño MD, Sanz AB, Martín-Cleary C, Ruiz-Ortega M, Egido J, Navarro-González JF, Ortiz A, Fernandez-Fernandez B.

J Clin Med. 2015 Jun 18;4(6):1325-47. doi: 10.3390/jcm4061325. Review.

27.

The Concept and the Epidemiology of Diabetic Nephropathy Have Changed in Recent Years.

Martínez-Castelao A, Navarro-González JF, Górriz JL, de Alvaro F.

J Clin Med. 2015 May 28;4(6):1207-16. doi: 10.3390/jcm4061207. Review.

28.

Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.

Barrios C, Pascual J, Otero S, Soler MJ, Rodríguez E, Collado S, Faura A, Mojal S, Navarro-González JF, Betriu A, Fernandez E, Valdivielso JM; investigators of the NEFRONA study.

Atherosclerosis. 2015 Sep;242(1):37-44. doi: 10.1016/j.atherosclerosis.2015.06.048. Epub 2015 Jun 30.

PMID:
26177272
29.

Inflammatory cytokines in diabetic nephropathy.

Donate-Correa J, Martín-Núñez E, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF.

J Diabetes Res. 2015;2015:948417. doi: 10.1155/2015/948417. Epub 2015 Feb 15. Review.

30.

Vascular calcification in patients with nondialysis CKD over 3 years.

Górriz JL, Molina P, Cerverón MJ, Vila R, Bover J, Nieto J, Barril G, Martínez-Castelao A, Fernández E, Escudero V, Piñera C, Adragao T, Navarro-Gonzalez JF, Molinero LM, Castro-Alonso C, Pallardó LM, Jamal SA.

Clin J Am Soc Nephrol. 2015 Apr 7;10(4):654-66. doi: 10.2215/CJN.07450714. Epub 2015 Mar 13.

31.

Implications of Klotho in vascular health and disease.

Martín-Núñez E, Donate-Correa J, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF.

World J Cardiol. 2014 Dec 26;6(12):1262-9. doi: 10.4330/wjc.v6.i12.1262. Review.

32.

Inflammation in diabetic kidney disease.

García-García PM, Getino-Melián MA, Domínguez-Pimentel V, Navarro-González JF.

World J Diabetes. 2014 Aug 15;5(4):431-43. doi: 10.4239/wjd.v5.i4.431. Review.

33.

Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial.

Navarro-González JF, Mora-Fernández C, Muros de Fuentes M, Chahin J, Méndez ML, Gallego E, Macía M, del Castillo N, Rivero A, Getino MA, García P, Jarque A, García J.

J Am Soc Nephrol. 2015 Jan;26(1):220-9. doi: 10.1681/ASN.2014010012. Epub 2014 Jun 26.

34.

Diabetic kidney disease: from physiology to therapeutics.

Mora-Fernández C, Domínguez-Pimentel V, de Fuentes MM, Górriz JL, Martínez-Castelao A, Navarro-González JF.

J Physiol. 2014 Sep 15;592(18):3997-4012. doi: 10.1113/jphysiol.2014.272328. Epub 2014 Jun 6. Review.

35.

Tunneled catheters with taurolidine-citrate-heparin lock solution significantly improve the inflammatory profile of hemodialysis patients.

Fontseré N, Cardozo C, Donate J, Soriano A, Muros M, Pons M, Mensa J, Campistol JM, Navarro-González JF, Maduell F.

Antimicrob Agents Chemother. 2014 Jul;58(7):4180-4. doi: 10.1128/AAC.02421-14. Epub 2014 May 12.

36.

Beneficial effects of selective vitamin D receptor activation by paricalcitol in chronic kidney disease.

Donate-Correa J, Domínguez-Pimentel V, Muros-de-Fuentes M, Mora-Fernández C, Martín-Núñez E, Cazaña-Pérez V, Navarro-González JF.

Curr Drug Targets. 2014;15(7):703-9. Review.

PMID:
24745821
37.

Selective vitamin D receptor activation as anti-inflammatory target in chronic kidney disease.

Donate-Correa J, Domínguez-Pimentel V, Méndez-Pérez ML, Muros-de-Fuentes M, Mora-Fernández C, Martín-Núñez E, Cazaña-Pérez V, Navarro-González JF.

Mediators Inflamm. 2014;2014:670475. doi: 10.1155/2014/670475. Epub 2014 Jan 6.

38.

Reduced Klotho is associated with the presence and severity of coronary artery disease.

Navarro-González JF, Donate-Correa J, Muros de Fuentes M, Pérez-Hernández H, Martínez-Sanz R, Mora-Fernández C.

Heart. 2014 Jan;100(1):34-40. doi: 10.1136/heartjnl-2013-304746. Epub 2013 Oct 28.

PMID:
24165855
39.

Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration.

Rodríguez-Ortiz ME, Canalejo A, Herencia C, Martínez-Moreno JM, Peralta-Ramírez A, Perez-Martinez P, Navarro-González JF, Rodríguez M, Peter M, Gundlach K, Steppan S, Passlick-Deetjen J, Muñoz-Castañeda JR, Almaden Y.

Nephrol Dial Transplant. 2014 Feb;29(2):282-9. doi: 10.1093/ndt/gft400. Epub 2013 Oct 8.

40.

Activation of vitamin D receptors in the optimization of hyperparathyroidism secondary to dialysis.

Herrero JA, López-Gómez JM, Maduell F, Martín-de Francisco ÁL, Martín-Malo A, Martínez-Castelao A, Navarro-González JF, Pérez-Fontán M, Pérez J, Selgas R, Solozabal C.

Nefrologia. 2013;33(4):571-84. doi: 10.3265/Nefrologia.pre2013.May.11901. Review. English, Spanish. No abstract available.

41.

Pathophysiological implications of fibroblast growth factor-23 and Klotho and their potential role as clinical biomarkers.

Donate-Correa J, Muros de Fuentes M, Mora-Fernández C, Navarro-González JF.

Clin Chem. 2014 Jul;60(7):933-40. doi: 10.1373/clinchem.2013.206649. Epub 2013 Jun 11. Review.

42.

ENaC modulators and renal disease.

Alvarez de la Rosa D, Navarro-González JF, Giraldez T.

Curr Mol Pharmacol. 2013 Mar;6(1):35-43. Review.

PMID:
23547933
43.

Anti-inflammatory profile of paricalcitol in hemodialysis patients: a prospective, open-label, pilot study.

Navarro-González JF, Donate-Correa J, Méndez ML, de Fuentes MM, García-Pérez J, Mora-Fernández C.

J Clin Pharmacol. 2013 Apr;53(4):421-6. doi: 10.1002/jcph.19. Epub 2013 Feb 20.

PMID:
23426718
44.

[Fibroblast growth factor 23/Klotho system in the context of cardiovascular damage].

Donate-Correa J, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF.

Med Clin (Barc). 2013 May 4;140(9):420-3. doi: 10.1016/j.medcli.2012.11.010. Epub 2013 Jan 18. Review. Spanish. No abstract available.

PMID:
23337450
45.

About the discrepancies between consensus documents, clinical practice guidelines, and legal regulations in the treatment of type 2 diabetes.

Martínez-Castelao A, Górriz JL, Sola E, Morillas C, Jover A, Coronel F, Navarro-González J, De Álvaro F.

Nefrologia. 2012 Jul 17;32(4):419-26. doi: 10.3265/Nefrologia.pre2012.Jun.11576. English, Spanish. No abstract available.

46.

Should we adjust erythropoiesis-stimulating agent dosage to postdialysis hemoglobin levels? A pilot study.

Castillo N, García-García P, Rivero A, Jiménez-Sosa A, Macía M, Getino MA, Méndez ML, García-Pérez J, Navarro-González JF.

BMC Nephrol. 2012 Jul 16;13:60. doi: 10.1186/1471-2369-13-60.

47.

FGF23/Klotho axis: phosphorus, mineral metabolism and beyond.

Donate-Correa J, Muros-de-Fuentes M, Mora-Fernández C, Navarro-González JF.

Cytokine Growth Factor Rev. 2012 Feb-Apr;23(1-2):37-46. doi: 10.1016/j.cytogfr.2012.01.004. Epub 2012 Feb 22. Review.

PMID:
22360923
48.

Relationship between inflammation and microalbuminuria in prehypertension.

Navarro-González JF, Mora C, Muros M, García J, Donate J, Cazaña V.

J Hum Hypertens. 2013 Feb;27(2):119-25. doi: 10.1038/jhh.2011.118. Epub 2012 Jan 26.

PMID:
22277919
49.

Pathophysiological role and therapeutic implications of inflammation in diabetic nephropathy.

Luis-Rodríguez D, Martínez-Castelao A, Górriz JL, De-Álvaro F, Navarro-González JF.

World J Diabetes. 2012 Jan 15;3(1):7-18. doi: 10.4239/wjd.v3.i1.7.

50.

Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy.

Sanchez-Niño MD, Bozic M, Córdoba-Lanús E, Valcheva P, Gracia O, Ibarz M, Fernandez E, Navarro-Gonzalez JF, Ortiz A, Valdivielso JM.

Am J Physiol Renal Physiol. 2012 Mar 15;302(6):F647-57. doi: 10.1152/ajprenal.00090.2011. Epub 2011 Dec 14.

Supplemental Content

Loading ...
Support Center